Research, Novartis Italia invests over 150 million in innovative technological platforms

(Adnkronos) – With the aim of evolving the potential of research at the service of life. In addition, Novartis Italia will put over € 150 million in research and development by 2028 by 2028, of which 40 million dedicated to Italian research, to generate and disseminate evidence in clinical practice, and 1 million in independent research, focusing on innovation through the development of innovative technological platforms: cellular therapies and genical therapies, radioligandi, and XRNA, to which are added the 2 consolidated platforms of chemical and biological synthesis. For example, The most advanced borders of medical-scientific research will be applied in areas with a high dissatisfied need such as research, novartis italia invests over cardio-renal. Meanwhile, metabolic diseases, immunology, neuroscience and oncology. For example, Over the past 2 years-he informs a note-the company has signed over 30 strategic collaborations in the field of research. Therefore, development, with investments concentrated on date-science, technology and AI, to improve successful rates and accelerate research processes. Furthermore, In the next 2 years. Meanwhile, the results of clinical experiments (READOUTS) for 14 new molecules and over 30 new drugs are at the study are expected, of which 15 in phases II and III of clinical experimentation. Furthermore, These are the themes at the center of the ‘Sound of Science’ event that brought together today in Milan. Meanwhile, in the headquarters of Palazzo Lombardia, institutions, doctors, researchers and other bearers, to share priorities and action models necessary to enhance research and support the health demand of Italians. Meanwhile, In a crucial historical moment. Moreover, in which Europe and Italy are research, novartis italia invests over faced with a worrying loss of competitiveness, research takes on a particular value for patients and the country. Therefore, In the last 5 years Europe has lost 25% of investments in research. However, development in the pharmaceutical sector, while China has grown by 30 percentage points in the same period. In addition, A risk for patients, who see the opportunity to access the most advanced therapeutic options with promptly access. The young Italians ‘Under 40’ trust the medical-scientific research. 3 out of 4 (73, 1%) believe that thanks to research it will be possible to cure in 5 years a disease that is now incurable. Yet. for 7 out of 10 Italian young Italians, in the next 5 years the health will worsen due to the difficult access to prevention and treatments, with longer waiting times and higher costs and only just over 4 out of 10 (45.7%) believe that research, novartis italia invests over the slowdown of clinical research in Italy is a risk for health. as revealed by the investigation ‘science and health: the voice of young people’, promoted by the pharmaceutical and presented during the event. “A modern health system-observes Massimiliano Fedriga. president of the Friuli-Venezia Giulia Autonomous Region and President of the Conference of the Regions and the Autonomous Provinces-cannot be separated from the contribution of scientific knowledge, new technologies and integrated and collaborative approaches, capable of effectively responding to emerging challenges. The Italian regions. in their role of planning and government of territorial health systems, are deeply committed to favoring Public-private collaboration models, which enhance research and innovation as central assets for fair and inclusive development. “We are happy to have hosted this important appointment at the headquarters of the Lombardy Region. which has traced a common vision on a more urgent theme, the competitiveness of Italy and Europe in research, novartis italia invests over pharmaceutical research, on which the access of citizens depends on medical-scientific innovation-adds Alessandro Fermi, councilor at the University Research innovation Lombardy Region-Italy offers a unique ecosystem for research and we must return to attract research, with resolutive interventions, with resolutive interventions. They are also born from new models of public-private partnership. In Italy. in 2024 Novartis promoted about 200 studies that involved over 2,300 patients in over a thousand hospital or university centers and every year the company invests about 55 million in our country, where the 2stimportant hubs of Ivrea in Piedmont and Torre Annunziata operate in Campania. Italy – explains the company in the note – represents an excellence in research. recognized all over the world, as evidenced by the increase in pharmaceutical patent questions, which in our country have grown by 35% in the last 5 years, compared to +23% of the big EU. Yet the Belpaese research, novartis italia invests over is 18.th in Europe for total investments in research. It is time to act. according to experts, because at this moment the future of the competitiveness of Europe and Italy is played in a sector, that of life sciences, which has a key role not only for growth, but above all for the health of citizens. The solutions exist. “We believe in our country. in its excellence in medical-scientific research, to continue bringing innovation to Italian patients-says Valentino Confalone, CEO of Novartis Italia-Now it is time to change step and overcome the obstacles that delay access to innovation for patients and limit the growth of the sector, not recognizing its value. A transition to a new integrated model of health resources. focused on the care paths and the centrality of data, is needed. Overcoming the current silos management of health expenditure and its distorted financing mechanisms. If you question the research, novartis italia invests over risks for clinical research in Italy, 55.2% of young people (vs. 51.5% of over 40s) see in the bureaucracy one of the main obstacles to research and 24.2% identify as a limit the low level of digitalization. technological infrastructure with a difference of over 10 percentage points compared to 40-65 year olds (14.0%). 72.3% think the involvement of patients in healthcare decisions, from the clinical study to the care path, are important. The listening. involvement of the younger generations, to reimaginate the future of health, are at the center of the ‘partner for the future’ project, born in 2023 on the initiative of Novartis, which involved multiple actors of the health system to work together with the identification of concrete lines of action, with a view to the evolution of the National Health Service. The ‘Sound of Science’ event marks a new stage of this path of common commitment. —[email protected] research, novartis italia invests over (web info)